17 min ago | SBWire
Growing Stock Report expands its NYSE Gainers Weekly Watch List adding Verizon Communications Inc. and Johnson & Johnson .
4 hrs ago | Illinoisreview
All posts, comments and statements made on IR are those of the authors only. Any disputes must be addressed to the writers, who are solely responsible for their posts, comments and statements.
8 hrs ago | Fox News
Pharmaceutical companies need to boost the benefits of drug research by working with regulators and healthcare providers to overhaul the way medicines are approved and paid for, a thinktank backed by investors says.
James is a member of The Motley Fool Blog Network -- entries represent the personal opinion of the blogger and are not formally edited.
Arkansas' attorney general filed a brief Tuesday backed by his counterparts in 35 other states asking the Arkansas Supreme Court to uphold a $1.2 billion fine levied against Johnson & Johnson and a subsidiary over the marketing of the antipsychotics drug Risperdal.
Arkansas Attorney General Dustin McDaniel is asking the state's highest court to uphold a $1.2 billion fine leveled against Johnson and Johnson and a subsidiary over the marketing of an antipsychotic drug.
The Food and Drug Administration is investigating two deaths that occurred after patients were injected with Eli Lilly & Co.
Speculative players have been taking sides on blue chip Johnson & Johnson , automaker General Motors Company , and Finnish telecom concern Nokia Corporation , according to data from the major options exchanges.
Aside from concerns about the company's valuation, I didn't feel comfortable about Johnson & Johnson's margins; nor did I feel that the company's top-selling drug, Zytiga, was the answer to long-term prosperity.
Johnson & Johnson said Thursday it has decided to buy Aragon Medication Inc. for at least $650 thousand in money, enhancing its position in prostate medication growth.The independently owned San Paul organization is targeted on the growth of medication to cure hormonally motivated malignancies.
The Food and Drug Administration said Friday it approved a next-generation silicone breast implant from Johnson & Johnson unit Mentor.
Johnson & Johnson said it would pay up to $1 billion for Aragon Pharmaceuticals and its experimental drugs for prostate cancer, to bolster J&J's role in the field after it acquired another experimental prostate-cancer treatment four years ago that has become a leading brand.
's stock had its "neutral" rating restated by equities researchers at Sterne Agee in a research report issued on Monday, StockRatingsNetwork.com reports.
Johnson & Johnson agreed to buy privately-held drug developer Aragon Pharmaceuticals for as much as $1 billion on Monday as it looks to build-out its portfolio of drugs that treat hormonally-driven diseases like prostate cancer.
British scientists have won early financial backing for a new kind of anticoagulant drug they believe may prevent dangerous blood clots without causing bleeding - a previously unachievable goal.
Johnson & Johnson's DePuy Synthes unit, a maker of artificial spinal repair products, won $16 million in damages from Globus Medical Inc. when a jury decided that three of its patents were infringed.